PT  - JOURNAL ARTICLE
AU  - M A Wilson
AU  - D W Gallager
TI  - Responses of substantia nigra pars reticulata neurons to benzodiazepine ligands after acute and prolonged diazepam exposure. II. Modulation of firing rate.
DP  - 1989 Feb 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 886--891
VI  - 248
IP  - 2
4099  - http://jpet.aspetjournals.org/content/248/2/886.short
4100  - http://jpet.aspetjournals.org/content/248/2/886.full
SO  - J Pharmacol Exp Ther1989 Feb 01; 248
AB  - We have examined the effects of chronic (3 week) and acute (1 hr) exposure to diazepam on firing rate responses of reticulata neurons to the inverse agonist methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) and the benzodiazepine antagonist Ro15-1788. The ability of DMCM and Ro15-1788 to alter firing rate were tested in control, chronic diazepam and acute diazepam-treated rats. In controls, DMCM increased firing rate of reticulata neurons. This effect was reversed by Ro15-1788, which had no effect on firing rate when administered alone. In acute and chronic diazepam-treated groups, low doses of DMCM were less effective in increasing firing than in controls. However, the administration of high doses of DMCM to diazepam-treated animals increased firing rates above the rates observed in control animals after the same compounds. Administration of Ro15-1788 also increased reticulata firing rates above control levels in both acute and chronic diazepam-treated groups. The similarity in reticulata responses after chronic (3 week) and acute (1 hr) diazepam treatments suggests that the altered properties of the benzodiazepine ligands observed after chronic exposure could reflect the presence of diazepam. This may indicate that reticulata neurons themselves do not show changes in sensitivity to benzodiazepine ligands after chronic benzodiazepine exposure. We propose that the altered responses to DMCM and Ro15-1788 in diazepam-treated rats reflect a compensatory change which occurs by 1 hr and maintains reticulata activity at a constant level throughout the period of prolonged exposure to the agonist.